Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial.

Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoüe A, Fratacci MD; PERFORM Study Investigators.

Lancet. 2011 Jun 11;377(9782):2013-22. doi: 10.1016/S0140-6736(11)60600-4. Epub 2011 May 25. Erratum in: Lancet. 2011 Jul 30;378(9789):402.

PMID:
21616527
2.

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.

Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici MG, Mattle HP, Rothwell PM; PERFORM Study Investigators.

Cerebrovasc Dis. 2009;27(5):509-18. doi: 10.1159/000212671. Epub 2009 Apr 16. Erratum in: .

PMID:
19372653
3.

NXY-059 for acute ischemic stroke.

Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hårdemark HG, Wasiewski WW; Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators.

N Engl J Med. 2006 Feb 9;354(6):588-600.

Supplemental Content

Loading ...
Support Center